Current Landscape of Clinical Diagnosis in Multiple System Atrophy
- 10 December 2024
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (11) , e210021
Abstract
Clinical diagnosis of multiple system atrophy (MSA) is challenging. In 2022, new diagnostic criteria for MSA were proposed. We hypothesized that the positive predictive value (PPV) of clinical diagnosis of MSA improved because of advanced diagnostic tools, including brain MRI. This study aimed to understand temporal changes in PPV of MSA. We conducted a retrospective analysis of patients clinically diagnosed with MSA whose brains were examined in the Mayo Clinic brain bank from 2008 to 2022. PPV was compared between 2 periods (2008-2017 and 2018-2022) and successively with a 4-year moving average. PPV for each clinical subtype (parkinsonism type [MSA-P] and cerebellar type [MSA-C]) was assessed. This study included 321 patients (136 women, age at death 68 ± 9 years) with a clinical diagnosis of MSA. Among them, 225 were pathologically confirmed as MSA, resulting in an overall PPV of 70%. The remaining 30% had alternative pathologic diagnoses including Lewy body disease (18%), progressive supranuclear palsy (4%), cerebrovascular disease (1%), corticobasal degeneration (1%), and others (6%). PPV improved from 63% in 2008-2017 to 78% in 2018-2022 (odds ratio [OR] 2.0 [1.2-3.5], p = 0.005). Linear analysis also demonstrated increased PPV over time (r = 0.66 [0.14-0.89], p = 0.02). Brain MRI scans were more frequently performed in 2018-2022 compared with 2008-2017 (91% vs 80%; OR 2.4 [1.2-5.0], p = 0.012). PPV was higher in patients with brain MRI compared with those without (73% vs 52%; OR 2.5 [1.3-4.9], p = 0.0057). PPV for MSA-C was similar in both groups (87% in 2008-2017 and 93% in 2018-2022), while that for MSA-P improved from 59% in 2008-2017 to 72% in 2018-2022 (OR 1.8 [1.0-3.2], p = 0.04). This study demonstrates an improvement in the PPV of MSA in recent years, potentially attributed to the increased use of brain MRI. Nevertheless, it also highlights that it remains difficult to make a correct diagnosis for some patients based on their clinical presentation. These findings provide a baseline for future clinicopathologic research on MSA.Keywords
This publication has 48 references indexed in Scilit:
- Frequency of Comorbid Pathologies and Their Clinical Impact in Multiple System AtrophyMovement Disorders, 2023
- Creutzfeldt–Jakob Disease Misdiagnosed as Multiple System AtrophyMovement Disorders Clinical Practice, 2023
- Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System AtrophyMovement Disorders, 2023
- The Movement Disorder Society Criteria for the Diagnosis of Multiple System AtrophyMovement Disorders, 2022
- Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related DisordersMovement Disorders, 2021
- Role of Magnetic Resonance Imaging in the Diagnosis of Multiple System AtrophyMovement Disorders Clinical Practice, 2016
- Multiple system atrophy: Prognostic indicators of survivalMovement Disorders, 2014
- Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degenerationJournal of Neurology, 1999
- Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy BodiesArchives of Neurology, 1998
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991